Platelet Activation and Reactivity in Acute Exacerbations of COPD

Radboud University Medical Center30 enrolled

Overview

Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of cardiovascular disease. Platelets contribute to acute cardiovascular events and atherosclerosis. When platelets are activated, they form complexes with monocytes. These platelet-monocyte complexes (PMCs) are an early process in atherothrombosis and promote inflammation. In COPD, platelet function in AE-COPD is scarcely studied. This study aims to address this gap by investigating platelet function and coagulation in patients with AE-COPD and after convalescence.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COPD Exacerbation

Interventions

Blood is drawnOTHER

Blood analyses

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>40 years * Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC \< 70% and less than 12% on reversibility testing\< Lower limit of normal (LLN)) * ≥10 pack years of smoking Exclusion Criteria: * Use of anti-coagulation or other platelet function inhibitors * Asthma * Chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE) * Malignancies

Outcomes

Primary Outcomes

Platelet activation: platelet expression of CD62P (P-selectin) and fibrinogen binding at baseline and upon ex vivo stimulation.